An interventional study of Evisit and Office visit in Acne Vulgaris, sponsored by Massachusetts General Hospital. Completed at 2 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2012-03-16.
Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Health services research
The purpose of this study is to test the efficacy, timeliness, and user satisfaction of an online "E-Visit" application that uses store-and-forward technology for acne patients requiring dermatologic care for their condition. Hypotheses:
Across the United States, a geographically mal-distributed workforce of Dermatologists exists, a problem that is projected to worsen. Patient access to dermatologic care is threatened. The dermatology workforce shortage has resulted in long wait times for patients, especially new patient visits and acute care cases.
Teledermatology has received much attention as a solution to the preceding problems. Teledermatology can reduce the burden of repeat office visits in chronic conditions by facilitating care from home. In this trial, a model incorporating store-and-forward technology is tested in general clinics while its impact on clinical outcomes, satisfaction, and wait times are studied.
Comparison: After consent, study subjects are assigned a unique study number and randomly assigned to one of two groups:
Group 1- The first group of subjects will have four (4) in-office visits spaced six weeks apart.
Group 2- The second group will have four (4) "e-visits" spaced six weeks apart.
At the end of study (after completion of 5th visit overall) all participants will complete a satisfaction survey.
730 studies on the registry are indexed under Acne Vulgaris; 86 are open to participants now.
This study's enrollment of 151 is above the median of 69 across 628 interventional studies indexed under Acne Vulgaris.
Browse Acne Vulgaris studies →Massachusetts General Hospital is the lead sponsor of 2,536 studies on the registry; 446 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 161 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Office Visits
Other: Office visit
Evisit
Other: Evisit
Asynchronous,remote care delivery via a secure web platform
Also known as: RelayHealth platform
Conventional office-based care
Peer review of subject images using the Total Inflammatory Lesion Count at the end of active recruitment
Time frame: 6 months
Subject satisfaction
Time frame: 6 months
Physician satisfaction
Time frame: 6 months
Timing of visits
Time frame: ongoing
This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital